SỬ DỤNG REMDESIVIR TRONG ĐIỀU TRỊ COVID 19 TẠI TRUNG TÂM HỒI SỨC COVID 19 TỈNH TIỀN GIANG (15/08/2021 – 15/10/2021)

Abstract

Objectives: To evaluate the treatment results of patients with indications to use Remdesivir at the Covid-19 Resuscitation Center in Tien Giang province.

Subjects and methods: Descriptive cross-sectional study. There were 181 cases with indications to use Remdesivir at the Covid-19 Resuscitation Center in Tien Giang Province from August 15, 2021, to October 15, 2021.

Results: The average age of the disease was 56.48 ± 15.74 years old; the age group over 50 was the most common, accounting for 62.71%. 61.86% of cases had underlying diseases. Females are more affected than males; the male/female ratio is 1/1.74. In the group using the drug late (> 6 days), there was a higher rate of disease, 1.18 times highercompared to using early in 1-3 days. The average number of days using Remdesivir was 6.66 ± 2.75 days, of which > 5 days accounted for 56.78%. The average number of vials of Remdesivir used was 7.66 ± 2.75 days, of which > 5 vials accounted for 83.05%. Glomerular filtration rate and liver function ALT did not change much before and after treatment. Remdesivir significantly reduced the patient's viral load. The average CT index and the number of days using Remdesivir were related; the difference was statistically significant with p < 0.05. Conclusions: Remdesivir used significantly reduced the patient's viral concentration, thereby shortening the duration of the disease and reducing the mortality rate; the drug did not affect liver function and the filtration rate. Because this is a new drug used, there have not been many studies on the effectiveness and side effects in patients, so more in-depth studies on this topic are needed.